DRX Fiber Capsules Recalled for Improper Storage Temperature Conditions
Family Dollar Stores is recalling DRX Fiber Capsules (100 CT) distributed nationwide April 30–June 10, 2022, due to improper storage temperature conditions that violate good manufacturing practice requirements.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported hospitalizations, illnesses, or injuries. The recall is precautionary in response to a CGMP deviation involving improper storage conditions, qualifying as a moderate-risk precautionary recall.
Plain-English summary
DRX Fiber Capsules 100 CT, manufactured by Family Dollar Stores, Llc., are being recalled because the product was held outside appropriate storage temperature conditions. This storage deviation violates Current Good Manufacturing Practice (CGMP) requirements established by the FDA.
The affected product was distributed nationwide through Family Dollar Stores between April 30, 2022, and June 10, 2022. The product is identified by SKU 998899.
Consumers who purchased this product should discontinue use and return it to the place of purchase or contact Family Dollar Stores, Llc. for a refund or replacement. No illnesses or injuries have been reported in connection with this recall.
The recalled product
- Product
- DRX FIBER CAPSULES 100 CT distributed to specific Family Dollar Stores 04/30/2022 through 06/10/2022.
- Manufacturer
- Family Dollar Stores, Llc.
- Category
- Drug — Dietary Supplement
- Hazard
- improper-storage
- temperature-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- SKU: 998899
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27